Published in J Gen Intern Med on April 05, 2013
Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation. PLoS Med (2015) 1.47
Pharmacists' Perceptions of the Influence of Interactions with the Pharmaceutical Industry on Clinical Decision-Making. Can J Hosp Pharm (2015) 1.38
A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada. Healthc Policy (2016) 0.97
Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS One (2014) 0.94
Pharmaceutical sales representatives and patient safety. J Gen Intern Med (2013) 0.90
Perceptions and Attitudes of Egyptian Health Professionals and Policy-Makers towards Pharmaceutical Sales Representatives and Other Promotional Activities. PLoS One (2015) 0.81
Key Features of Academic Detailing: Development of an Expert Consensus Using the Delphi Method. Am Health Drug Benefits (2016) 0.81
Association between physicians' interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis. PLoS One (2017) 0.78
Salespeople in the Surgical Suite: Relationships between Surgeons and Medical Device Representatives. PLoS One (2016) 0.78
Pharmaceutical sales representatives and patient safety. J Gen Intern Med (2013) 0.77
Interactions between medical residents and drug companies: a national survey after the Mediator® affair. PLoS One (2014) 0.75
Design and evaluation of a software for the objective and easy-to-read presentation of new drug properties to physicians. BMC Med Inform Decis Mak (2015) 0.75
Unhealthy marketing of pharmaceutical products: An international public health concern. J Public Health Policy (2016) 0.75
Unwarranted claims of drug efficacy in pharmaceutical sales visits: Are drugs approved on the basis of surrogate outcomes promoted appropriately? Br J Clin Pharmacol (2017) 0.75
The relation between promotional spending on drugs and their therapeutic gain: a cohort analysis. CMAJ Open (2017) 0.75
Understanding Users in the 'Field' of Medications. Pharmacy (Basel) (2016) 0.75
Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA (2000) 19.89
The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med (2008) 5.13
Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med (2010) 4.42
The accuracy of drug information from pharmaceutical sales representatives. JAMA (1995) 4.34
What information do physicians receive from pharmaceutical representatives? Can Fam Physician (1997) 2.06
Following the script: how drug reps make friends and influence doctors. PLoS Med (2007) 2.03
The lessons of Vioxx--drug safety and sales. N Engl J Med (2005) 1.88
Development of a standardized, comprehensive "ideal drug detail". Can J Clin Pharmacol (2001) 1.52
Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia. BMC Public Health (2010) 1.15
Factors associated with physicians' reliance on pharmaceutical sales representatives. Acad Med (2009) 1.09
Experience of VA psychiatrists with pharmaceutical detailing of antipsychotic medications. Psychiatr Serv (2007) 0.92
Industry sponsorship and research outcome. Cochrane Database Syst Rev (2012) 7.44
Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA (2005) 6.90
The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med (2008) 5.13
The pharmaceutical industry as a medicines provider. Lancet (2002) 5.07
The conceptual basis for interprofessional collaboration: core concepts and theoretical frameworks. J Interprof Care (2005) 4.65
Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med (2010) 4.42
How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ (2003) 4.08
Open letter to the leader of academic medicine. BMJ (2007) 4.06
Operational definitions of attributes of primary health care: consensus among Canadian experts. Ann Fam Med (2007) 3.85
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs. CMAJ (2003) 3.32
Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey. BMJ (2002) 3.15
The determinants of successful collaboration: a review of theoretical and empirical studies. J Interprof Care (2005) 3.10
New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med (2012) 2.81
Physician awareness of drug cost: a systematic review. PLoS Med (2007) 2.63
Prices don't drive regional Medicare spending variations. Health Aff (Millwood) (2010) 2.44
Practice features associated with patient-reported accessibility, continuity, and coordination of primary health care. Ann Fam Med (2008) 2.37
A systematic review of studies comparing health outcomes in Canada and the United States. Open Med (2007) 2.26
Medicare payments for common inpatient procedures: implications for episode-based payment bundling. Health Serv Res (2010) 2.18
Conflict of Interest Disclosure Policies and Practices in Peer-reviewed Biomedical Journals. J Gen Intern Med (2006) 2.03
Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosom Med (2008) 1.88
Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer (2009) 1.81
Inaccessibility of drug reports. CMAJ (2002) 1.69
Educating health professionals about drug and device promotion: advocates' recommendations. PLoS Med (2006) 1.68
Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med (2009) 1.62
Adverse drug events: counting is not enough, action is needed. Med J Aust (2006) 1.54
Hypertension outcomes through blood pressure monitoring and evaluation by pharmacists (HOME study). J Gen Intern Med (2005) 1.51
Validation of instruments to evaluate primary healthcare from the patient perspective: overview of the method. Healthc Policy (2011) 1.51
Higher health care quality and bigger savings found at large multispecialty medical groups. Health Aff (Millwood) (2010) 1.45
Developing personal values: trainees' attitudes toward strikes by health care providers. Acad Med (2011) 1.45
CJEM and pharmaceutical advertisements: it's time for an end. CJEM (2009) 1.44
Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA (2011) 1.44
Poor reporting of scientific leadership information in clinical trial registers. PLoS One (2008) 1.44
The essential and potentially inappropriate use of antipsychotics across income groups: an analysis of linked administrative data. Can J Psychiatry (2012) 1.41
A hypertensive snow bird. CMAJ (2005) 1.39
Pharmaceutical company advertising in The Lancet. Lancet (2011) 1.39
Physician awareness of diagnostic and nondrug therapeutic costs: a systematic review. Int J Technol Assess Health Care (2008) 1.38
The cost of drug development: a systematic review. Health Policy (2011) 1.37
'Linkage' pharmaceutical evergreening in Canada and Australia. Aust New Zealand Health Policy (2007) 1.26
An overview of confirmatory factor analysis and item response analysis applied to instruments to evaluate primary healthcare. Healthc Policy (2011) 1.21
Relational continuity from the patient perspective: comparison of primary healthcare evaluation instruments. Healthc Policy (2011) 1.21
The siren call of new drugs. Expert Rev Pharmacoecon Outcomes Res (2003) 1.21
Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine (2006) 1.20
Integration of the recommendations of the Canadian Task Force on Preventive Health Care: obstacles perceived by a group of family physicians. Fam Pract (2004) 1.20
Accessibility from the patient perspective: comparison of primary healthcare evaluation instruments. Healthc Policy (2011) 1.20
Financial Conflicts of Interest Checklist 2010 for clinical research studies. Open Med (2010) 1.19
Physician communication regarding prostate cancer screening: analysis of unannounced standardized patient visits. Ann Fam Med (2013) 1.17
Development and implementation of training for interdisciplinary research in primary health care. Acad Med (2010) 1.17
Patients' experience of chronic illness care in a network of teaching settings. Can Fam Physician (2012) 1.13
Canadian Experts' Views on the Importance of Attributes within Professional and Community-Oriented Primary Healthcare Models. Healthc Policy (2011) 1.13
Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ (2012) 1.11
The quantity and quality of scientific graphs in pharmaceutical advertisements. J Gen Intern Med (2003) 1.08
Medications for obesity. Can Fam Physician (2008) 1.07
Room for improvement: patients' experiences of primary care in Quebec before major reforms. Can Fam Physician (2007) 1.06
Complete dissociation from the health care and pharmaceutical industry. Can Fam Physician (2015) 1.06
How well do Canadian media outlets convey medical treatment information?: Initial findings from a year and a half of media monitoring by Media Doctor Canada. Open Med (2008) 1.06
Comprehensiveness of care from the patient perspective: comparison of primary healthcare evaluation instruments. Healthc Policy (2011) 1.05
The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol (2011) 1.05
At the interface of community and healthcare systems: a longitudinal cohort study on evolving health and the impact of primary healthcare from the patient's perspective. BMC Health Serv Res (2010) 1.04
The development of self-efficacy beliefs during general practice vocational training: an exploratory study. Med Teach (2009) 1.02
Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med (2013) 1.01
Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy. Res Social Adm Pharm (2005) 1.01
Investigator experiences with financial conflicts of interest in clinical trials. Trials (2011) 0.98
Impact of a randomized controlled educational trial to improve physician practice behaviors around screening for inherited breast cancer. J Gen Intern Med (2014) 0.98
Will lower drug prices jeopardize drug research? A policy fact sheet. Am J Bioeth (2004) 0.96
Core competencies for shared decision making training programs: insights from an international, interdisciplinary working group. J Contin Educ Health Prof (2013) 0.96
Implementation outcomes of a multiinstitutional web-based ethical, legal, and social implications genetics curriculum for primary care residents in three specialties. Genet Med (2011) 0.96
Antimicrobial use control measures to prevent and control antimicrobial resistance in US hospitals. Infect Control Hosp Epidemiol (2006) 0.95
Too few, too weak: conflict of interest policies at Canadian medical schools. PLoS One (2013) 0.95
Foreign free riders and the high price of US medicines. BMJ (2005) 0.95
The doctoring curriculum at the University of California, Davis School Of Medicine: leadership and participant roles for psychiatry faculty. Acad Psychiatry (2008) 0.95
["Serious" adverse drug reactions with tramadol: a 2010-2011 pharmacovigilance survey in France]. Therapie (2013) 0.95
Effects of depression and pain severity on satisfaction in medical outpatients: analysis of the Medical Outcomes Study. J Rehabil Res Dev (2007) 0.94
Pitching doctors. N Y Times Mag (1989) 0.94
Pandemrix°, (H1N1)v influenza and reported cases of narcolepsy. Vaccine (2011) 0.93
Do higher drug costs lead to better health? Can J Clin Pharmacol (2005) 0.92
Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J Law Med Ethics (2013) 0.91
Respectfulness from the patient perspective: comparison of primary healthcare evaluation instruments. Healthc Policy (2011) 0.91
Management continuity from the patient perspective: comparison of primary healthcare evaluation instruments. Healthc Policy (2011) 0.90
Institutional financial conflicts of interest policies at Canadian academic health science centres: a national survey. Open Med (2010) 0.90
Regulating prescription drugs for patient safety: does Bill C-17 go far enough? CMAJ (2014) 0.90
New directions in drug approval. CMAJ (2004) 0.89
Self-management practices among primary care patients with musculoskeletal pain and depression. J Behav Med (2008) 0.89
Influenza vaccination of health care workers. CMAJ (2013) 0.88
Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross-sectional study. Pharmacoepidemiol Drug Saf (2013) 0.88
Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents: a descriptive study using the French Pharmacovigilance database. Fundam Clin Pharmacol (2012) 0.88
Treatment preferences in patients with first episode depression. J Affect Disord (2012) 0.88
Ethnic disparities in antipsychotic drug use in British Columbia: a cross-sectional retrospective study. Psychiatr Serv (2011) 0.87
A randomized, controlled pragmatic trial of telephonic medication therapy management to reduce hospitalization in home health patients. Health Serv Res (2014) 0.87
The association between a journal's source of revenue and the drug recommendations made in the articles it publishes. CMAJ (2011) 0.86
Trends of reporting of 'serious'vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database. Br J Clin Pharmacol (2012) 0.85
The roulette wheel: an aid to informed decision making. PLoS Med (2006) 0.85
Is Australia's national medicines policy failing? The case of COX-2 inhibitors. Int J Health Serv (2007) 0.85
Assessing the quality of drug detailing. J Clin Epidemiol (2002) 0.85
Qualitative research and the politics of knowledge in an age of evidence: developing a research-based practice of immanent critique. Soc Sci Med (2008) 0.84
Primary and secondary care: Breaking down barriers for our patients with chronic diseases. Can Fam Physician (2013) 0.84
Regionalization in Canada: a promising heritage to build on. Healthc Pap (2004) 0.84
Mapping the coverage of attributes in validated instruments that evaluate primary healthcare from the patient perspective. BMC Fam Pract (2012) 0.84
What do Canadians think about physician-pharmaceutical industry interactions? Health Policy (2013) 0.84
Off-Label Drug Use: Whose Interests Are Served? Am J Med Qual (2016) 0.83
Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals. Pharmacoepidemiol Drug Saf (2011) 0.83